Skip to main content

Table 1 Summary of characteristics in studies into a meta-analysis

From: The relationship between metabolic syndrome and increased risk of Barrett’s esophagus: an updated systematic review and meta-analysis

Ref.

First author, Published Year

Design

Year of study

Place

Study setting

Special groups

Controls groups

criteria for MetS

Sample size

Effect size

QS

All

Case

Control

OR

95% CI

All

M,F

All

M,F

[10]

Lee SW, 2017

Cross-sectional

2006–9

Taiwan

Population_based

 

Endoscopy control

IDF

6594

95

61:34

6499

3447:3052

2.7

1.97

3.71

8

[11]

Healy L.A, 2010

Case-control

2003

Ireland

Hospital_based

–

Control with reflux symptoms

IDF

231

118

79: 39

113

67: 46

1.2

0.707

2.037

8

[12]

Wani SB, 2008

Case-control

NR

USA

Hospital_based

93.2% Caucasians

Control with reflux symptoms

Not mentioned

309

103

 

206

 

0.659

0.406

1.068

7

[13]

Duggan C, 2013

Cohort

1995–2009

USA

Hospital_based

96.4% White

BE baseline

IDF

388

    

1.14

0.56

2.36

7

[14]

Drahos J, 2015

Cross-sectional

2009

USA

Population_based

87.4% White

Endoscopy control

NCEP-ATP III

8792

2198

1150:1048

6594

3450:3144

1.2

1.07

1.36

9

[14]

Drahos J, 2015

Cross-sectional

2009

USA

Population_based

85.3% White

Endoscopy control

NCEP-ATP III

8170

2198

1150:1048

5972

3036:2936

0.93

0.83

1.04

9

[15]

Leggett CL, 2013

Case-control

1999–2006

USA

Population_based

96.4% Caucasians

Control without reflux symptoms

IDF and WHO

206

103

70:33

103

70:33

1.9

1.03

3.6

8

[15]

Leggett CL, 2013

Case-control

1999–2006

USA

Population_based

96.4% Caucasians

Control with reflux symptoms

IDF and WHO

206

103

70:33

103

70:33

2.0

1.1

3.65

8

[16]

Thrift AP, 2015

Case-control

2008–2011

USA

Hospital_based

100% White man

Colonoscopy control

NCEP-ATP III

453

244

 

209

 

1.67

1.1

2.55

8

[16]

Thrift AP, 2015

Case-control

2008–2011

USA

Hospital_based

100% White man

Endoscopy control

NCEP-ATP III

859

244

 

615

 

0.87

0.49

1.54

8

[17]

Drahos J, 2016

Cross-sectional

1992–2012

United Kingdom

Population_based

 

Endoscopy control

NCEP-ATP III

60,382

10,215

6399:3816

50,167

31,375:18792

1.12

1.0

1.25

8

[18]

Wu P-C, 2019

Cross-sectional

2016–2018

South Korea

Population_based

 

Endoscopy control

IDF

4943

88

66:22

4855

2475:2380

2.07

1.29

3.33

9

[19]

Drahos J, 2017

Cross-sectional

2003–2009

USA

Population_based

 

Endoscopy control

NCEP-ATP III

16,410

575

 

15,835

 

1.318

1.098

1.583

9

[20]

Kendall B, 2010

Case-control

2003–6

Australia

Population_based

 

Endoscopy control

Not mentioned

473

236

 

237

 

1.91

1.32

2.76

6

  1. MetS Metabolic Syndrome, M,F Male, female, QS Quality Score, OR Odds Ratio, CI Confidence Interval, IDF International Diabetes Federation, WHO World Health Organization, NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III, LA Los Angeles classification, NR Not Reported
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us